Neuland Laboratories Share Price Today (NEULANDLAB)
TODAY IN ONE LINE
NEULANDLAB slipped 0.7% on light volume, in line with Nifty's -0.0% move, supported by recent strong earnings.
With a market cap of ₹24,222.83 Cr., it trades at a P/E of 66.90. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Neuland Laboratories flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 664.4% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 136.0% and Profit up 665.0%
- ●High Capital EfficiencyROCE of 26.6% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 21.4%
- ●Healthy Operating MarginsOPM is structurally strong at 28.4%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 66.3x
- ●FII SellingFII holding decreased by 1.09% QoQ
- ●Promoter Pledging DetectedPledge activity recorded on 26-Mar-2026 15:54
Latest Neuland Laboratories News
What changed recently?
Recent events, corporate actions, and announcements.
Neuland Laboratories Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Neuland Laboratories Limited, framed against the sector median so the premium or discount is obvious at a glance.
Neuland Laboratories Limited trades at a P/E of 66.90× and P/B of 12.99×, against the Healthcare sector median P/E of 45.48×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Neuland Laboratories Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Neuland Laboratories Limited — derived from the live tape, not yesterday's close.
Neuland Laboratories Limited last traded at ₹18,871 with an intraday range of ₹18,674–₹19,117 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹18871.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 19986.67 | +1115.67 | +5.91% |
| R3 | 19543.67 | +672.67 | +3.56% |
| R2 | 19330.33 | +459.33 | +2.43% |
| R1 | 19100.67 | +229.67 | +1.22% |
| PIVOT | 18887.33 | 16.33 | 0.09% |
| CURRENT | 18871.00 | — | — |
| S1 | 18657.67 | -213.33 | -1.13% |
| S2 | 18444.33 | -426.67 | -2.26% |
| S3 | 18214.67 | -656.33 | -3.48% |
| S4 | 17771.67 | -1099.33 | -5.83% |
NEULANDLAB is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹18674–₹19117
Trading Inside opening range
Neuland Laboratories Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Neuland Laboratories Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Neuland Laboratories Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹24,222.83 Cr. and reported EPS of ₹293.13.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,477 | 2,023 ▲ 37.0% |
| Sales Growth YoY %Derived | -5.24% | 36.98% |
| Other Income | 21 | 30 ▲ 47.1% |
| Total Income | 1,497 | 2,053 ▲ 37.1% |
| 588 | 756 ▲ 28.6% | |
| Gross ProfitDerived | 889 | 1,267 ▲ 42.5% |
| Gross Margin %Derived | 60.21% | 62.65% |
| 566 | 693 ▲ 22.4% | |
| EBITDA (Operating Profit)Derived | 323 | 574 ▲ 77.7% |
| OPM %Derived | 21.89% | 28.40% |
| 150 | 116 ▼ 23.0% | |
| Profit Before Tax (PBT) | 346 | 489 ▲ 41.2% |
| 86 | 125 ▲ 45.0% | |
| Effective Tax %Derived | 24.90% | 25.56% |
| Total Profit for Period | 260 | 364 ▲ 39.9% |
| Net Profit (Owner's PAT)Derived | 260 | 364 ▲ 39.9% |
| Net Profit Margin %Derived | 17.61% | 17.99% |
| PAT Growth YoY %Derived | -13.32% | 39.94% |
| Earnings Per Share (EPS ₹) | 202.74 | 283.71 ▲ 39.9% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | 1 ▲ 2475.2% |
| Total Expenses (incl. D&A & Interest) | 1,151 | 1,564 ▲ 35.9% |
| Material Cost % of RevenueDerived | 38.92% | 40.52% |
| Employee Cost % of RevenueDerived | 18.42% | 16.86% |
| Other Cost % of RevenueDerived | 19.90% | 17.39% |
| Interest Coverage (x)Derived | 31.06x | 20.16x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 667 | 763 ▲ 14.4% | 937 ▲ 22.8% | 951 ▲ 1.5% | 1,191 ▲ 25.2% | 1,559 ▲ 30.8% | 1,477 ▼ 5.2% | 2,023 ▲ 37.0% | |
| Sales Growth YoY %Derived | — | 14.38% | 22.84% | 1.51% | 25.25% | 30.84% | -5.24% | 36.98% | |
| Other Income | 3 | 4 ▲ 11.3% | 16 ▲ 314.2% | 2 ▼ 87.1% | 10 ▲ 369.4% | 13 ▲ 28.7% | 21 ▲ 63.5% | 30 ▲ 47.1% | |
| Total Income | 670 | 767 ▲ 14.4% | 953 ▲ 24.3% | 953 ▲ 0.0% | 1,201 ▲ 26.0% | 1,571 ▲ 30.8% | 1,497 ▼ 4.7% | 2,053 ▲ 37.1% | |
366 | 380 ▲ 3.8% | 438 ▲ 15.3% | 422 ▼ 3.7% | 478 ▲ 13.3% | 577 ▲ 20.7% | 588 ▲ 1.8% | 756 ▲ 28.6% | ||
| Gross ProfitDerived | 301 | 383 ▲ 27.3% | 499 ▲ 30.3% | 529 ▲ 6.1% | 713 ▲ 34.8% | 981 ▲ 37.6% | 889 ▼ 9.4% | 1,267 ▲ 42.5% | |
| Gross Margin %Derived | 45.08% | 50.15% | 53.21% | 55.61% | 59.85% | 62.96% | 60.21% | 62.65% | |
242 | 281 ▲ 15.9% | 352 ▲ 25.3% | 386 ▲ 9.8% | 441 ▲ 14.2% | 519 ▲ 17.6% | 566 ▲ 9.1% | 693 ▲ 22.4% | ||
| EBITDA (Operating Profit)Derived | 58 | 102 ▲ 74.6% | 147 ▲ 44.1% | 143 ▼ 2.9% | 272 ▲ 90.6% | 463 ▲ 70.2% | 323 ▼ 30.1% | 574 ▲ 77.7% | |
| OPM %Derived | 8.75% | 13.36% | 15.67% | 15.00% | 22.82% | 29.68% | 21.89% | 28.40% | |
42 | 53 ▲ 27.3% | 58 ▲ 8.9% | 63 ▲ 8.6% | 66 ▲ 5.3% | 74 ▲ 11.9% | 150 ▲ 103.9% | 116 ▼ 23.0% | ||
| Profit Before Tax (PBT) | 20 | 53 ▲ 160.2% | 105 ▲ 99.0% | 82 ▼ 22.0% | 216 ▲ 162.6% | 401 ▲ 86.1% | 346 ▼ 13.7% | 489 ▲ 41.2% | |
4 | 37 ▲ 842.4% | 25 ▼ 32.7% | 18 ▼ 25.8% | 52 ▲ 184.8% | 101 ▲ 94.1% | 86 ▼ 14.9% | 125 ▲ 45.0% | ||
| Effective Tax %Derived | 19.16% | 69.37% | 23.45% | 22.32% | 24.21% | 25.25% | 24.90% | 25.56% | |
| Total Profit for Period | 16 | 16 ▼ 1.4% | 81 ▲ 397.4% | 64 ▼ 20.8% | 164 ▲ 156.2% | 300 ▲ 83.5% | 260 ▼ 13.3% | 364 ▲ 39.9% | |
| Net Profit (Owner's PAT)Derived | 16 | 16 ▼ 1.4% | 81 ▲ 397.4% | 64 ▼ 20.8% | 164 ▲ 156.2% | 300 ▲ 83.5% | 260 ▼ 13.3% | 364 ▲ 39.9% | |
| Net Profit Margin %Derived | 2.47% | 2.13% | 8.61% | 6.71% | 13.73% | 19.25% | 17.61% | 17.99% | |
| PAT Growth YoY %Derived | — | -1.41% | 397.40% | -20.85% | 156.21% | 83.51% | -13.32% | 39.94% | |
| Earnings Per Share (EPS ₹) | 12.82 | 12.63 ▼ 1.5% | 62.85 ▲ 397.6% | 49.74 ▼ 20.9% | 127.45 ▲ 156.2% | 233.89 ▲ 83.5% | 202.74 ▼ 13.3% | 283.71 ▲ 39.9% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 236.6% | -2 ▼ 260.5% | -6 ▼ 279.0% | -4 ▲ 40.9% | 1 ▲ 138.8% | -0 ▼ 103.3% | 1 ▲ 2475.2% | |
| Total Expenses (incl. D&A & Interest) | 650 | 714 ▲ 9.8% | 848 ▲ 18.8% | 871 ▲ 2.8% | 985 ▲ 13.1% | 1,170 ▲ 18.7% | 1,151 ▼ 1.6% | 1,564 ▲ 35.9% | |
| Material Cost % of RevenueDerived | 54.05% | 51.31% | 46.93% | 46.01% | 40.94% | 40.58% | 38.92% | 40.52% | |
| Employee Cost % of RevenueDerived | 16.56% | 16.20% | 15.98% | 19.19% | 16.94% | 16.49% | 18.42% | 16.86% | |
| Other Cost % of RevenueDerived | 19.76% | 20.59% | 21.55% | 21.43% | 20.09% | 16.79% | 19.90% | 17.39% | |
| Interest Coverage (x)Derived | 2.08x | 3.27x | 5.99x | 6.93x | 16.76x | 28.78x | 31.06x | 20.16x |
Neuland Laboratories segment analysis : revenue and profit mix.
Disclosed business segments at Neuland Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Neuland Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Neuland Laboratories Limited.
Our AI distills the core fundamental drivers supporting Neuland Laboratories Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Neuland Laboratories Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 28.40% latest quarter significantly exceeds peer median 18.18%.
TTM EPS grew 664.4% YoY, demonstrating explosive earnings momentum and capital efficiency.
Debt-to-equity ratio 0.0016x indicates fortress-like balance sheet with minimal leverage.
ROCE 26.60% outpaces peer median ~18%, reflecting efficient capital deployment in manufacturing.
Net profit margin 17.99% TTM competitive within pharmaceutical sector, stable profitability.
Key Risks.
Latest quarterly EPS declined 83.1% YoY despite 136% revenue growth, earnings volatility.
Latest quarterly sales declined 33.4% YoY, significant near-term revenue contraction signal.
P/E ratio 66.26x far exceeds peer median 28.95x, severely overvalued on earnings basis.
EV/EBITDA 28.65x above peer median 23.2x, expensive valuation multiple signals overpricing.
Price-to-book 13.38x versus peer median 3.26x indicates substantial overvaluation risk.
Flip Conditions.
Valuation risk. a P/E above 87 (~1.9× the sector multiple of 45.5) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 16% would indicate weaker capital compounding.
Neuland Laboratories Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Neuland Laboratories Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Neuland Laboratories Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Neuland Laboratories Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Neuland Laboratories Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Neuland Laboratories Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Neuland Laboratories Limited stood at 55.9% of traded volume, against a 20-day average of 41.5%.
Neuland Laboratories announcements: results, concalls, ratings, M&A.
Filings Neuland Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Neuland Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 154 documents below.
Loss of Share Certificates
Neuland Laboratories Limited has informed the Exchange about Loss of Share Certificates
Credit Rating
Neuland Laboratories Limited has informed the Exchange about Credit Rating
Copy of Newspaper Publication
Newspaper publication regarding dispatch of notice of 42nd Annual General Meeting and Integrated Annual Report for FY 2025-26
Updates
Neuland Laboratories Limited has informed the Exchange regarding 'Letter to the Shareholders of the Company in relation to the Notice of 42nd Annual…
Updates
Neuland Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for FY 2025-26'.
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Neuland Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Neuland Laboratories has declared, sequenced by announce and record date.
Neuland Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Neuland Laboratories insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Neuland Laboratories as reported to SEBI — buying and selling signals from the people who know the business best.
Neuland Laboratories insider activity below tracks 12 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr. | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr. | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr. | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr. | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 04 Mar 2026 | buy | +12.5 K | — | — |
| Deepthi Davuluri | Insider | 04 Mar 2026 | buy | +12.5 K | — | — |
| Davuluri Ownership Trust | Insider | 28 Feb 2025 | buy | +79.5 K | — | — |
| Saharsh Rao Davuluri | Insider | 28 Feb 2025 | sell | −79.5 K | — | — |
| Sucheth Rao Davuluri | Insider | 25 Feb 2025 | sell | −79.6 K | — | — |
| Davuluri Ownership Trust | Insider | 25 Feb 2025 | buy | +32.54 L | — | — |
About Neuland Laboratories Limited: business, sector, key facts.
What Neuland Laboratories Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Neuland Laboratories Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NEULANDLAB, BSE: 524558.
Neuland Laboratories Limited is a global manufacturer and supplier of active pharmaceutical ingredients (APIs). Its primary business centers around the production and distribution of these essential components used in the creation of pharmaceutical drugs. The company serves a broad international market, with operations spanning India, Europe, the United States, and other countries around the world, signifying a significant global reach and established distribution network.
A key aspect of Neuland Laboratories' business model is its provision of custom manufacturing solutions. This service allows pharmaceutical companies to outsource the production of specific APIs tailored to their unique needs and formulations. This approach offers flexibility and scalability to clients, enabling them to focus on research, development, and marketing while leveraging Neuland's manufacturing expertise and infrastructure.
Further enhancing its service portfolio, Neuland Laboratories offers specialized peptide synthesis services. Peptides are short chains of amino acids that play crucial roles in various biological processes, making them important components in a range of therapeutic applications. The company's proficiency in this area demonstrates a commitment to advanced pharmaceutical technologies and a capability to cater to the increasing demand for complex pharmaceutical molecules.
Established in 1984 and headquartered in Hyderabad, India, Neuland Laboratories has a long history in the pharmaceutical industry. This long-standing presence suggests experience in navigating regulatory landscapes, managing complex production processes, and building strong relationships with clients and regulatory bodies across different global markets. The company’s sustained operation and global footprint highlight its ability to adapt and thrive in a dynamic and competitive industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Neuland Laboratories Limited (NEULANDLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Neuland Laboratories Limited (NEULANDLAB)?
The current share price of Neuland Laboratories Limited (NEULANDLAB) is ₹18,871. Today, the stock has declined by ₹123.00 (0.65%), trading in a range of ₹18,674 to ₹19,117. The stock opened at ₹18,978 with a trading volume of 15,593 shares.
02Is Neuland Laboratories Limited stock a good investment for long-term?
Neuland Laboratories Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹24,222.83 crores, P/E ratio of 66.90, ROE of 21.40%, and ROCE of 26.60%. The dividend yield stands at 0.06%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Neuland Laboratories Limited stock?
The 52-week high price of Neuland Laboratories Limited (NEULANDLAB) is ₹20,089, while the 52-week low is ₹11,500. Currently trading at ₹18,871, the stock is 85.8% away from its 52-week low and 6.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Neuland Laboratories Limited stock at the current price?
Whether to buy Neuland Laboratories Limited stock at ₹18,871 depends on multiple factors. The stock is currently trading with a P/E ratio of 66.90 and P/B ratio of 12.99. Today's performance shows a loss of 0.65%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Neuland Laboratories Limited and when is the next dividend?
Neuland Laboratories Limited offers a dividend yield of 0.06%, which means for every ₹100 invested at the current price of ₹18,871, you can expect to receive approximately ₹0.06 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Neuland Laboratories Limited?
Neuland Laboratories Limited's key financial metrics include: P/E Ratio: 66.90, P/B Ratio: 12.99, ROE: 21.40%, ROCE: 26.60%, Dividend Yield: 0.06%, EPS: ₹293.13, Book Value: ₹1,460.02, and Debt-to-Equity: 0.16. The company's market cap stands at ₹24,222.83 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Neuland Laboratories Limited stock performing today in the market?
Neuland Laboratories Limited stock opened at ₹18,978 and is currently trading at ₹18,871, showing a decline of ₹123.00 (0.65%). The intraday high is ₹19,117 and low is ₹18,674. The trading volume stands at 15,593 shares, indicating moderate market participation today.
08What is the P/E ratio of Neuland Laboratories Limited and what does it indicate?
Neuland Laboratories Limited has a Price-to-Earnings (P/E) ratio of 66.90, which means investors are willing to pay ₹66.90 for every ₹1 of earnings. With an EPS of ₹293.13, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Neuland Laboratories Limited (NEULANDLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.